40.01
+2.69(+7.21%)
Currency In USD
| Previous Close | 37.32 |
| Open | 38.85 |
| Day High | 41.95 |
| Day Low | 38.49 |
| 52-Week High | 44 |
| 52-Week Low | 13.46 |
| Volume | 59,680 |
| Average Volume | 13,759 |
| Market Cap | 104.71M |
| PE | -12.12 |
| EPS | -3.3 |
| Moving Average 50 Days | 32.59 |
| Moving Average 200 Days | 21.95 |
| Change | 2.69 |
If you invested $1000 in vTv Therapeutics Inc. (VTVT) 10 years ago, it would be worth $150.41 as of January 15, 2026 at a share price of $40.01. Whereas If you bought $1000 worth of vTv Therapeutics Inc. (VTVT) shares 5 years ago, it would be worth $478.59 as of January 15, 2026 at a share price of $40.01.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
GlobeNewswire Inc.
Dec 18, 2025 9:05 PM GMT
Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2DHIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
GlobeNewswire Inc.
Oct 09, 2025 12:00 PM GMT
Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trialsHIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical com
vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
GlobeNewswire Inc.
Sep 15, 2025 12:00 PM GMT
Company to share new independent research on TTP-RA, vTv’s oral RAGE antagonistHIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced that the company will